Abstract 76P
Background
Cancer of unknown primary (CUP) is a metastatic cancer without a primary site diagnosis after standardized investigations. Genomic testing can inform both treatment targets and identify the primary tissue of origin (TOO). Whole-genome sequencing (WGS) can increase diagnostic yield over DNA panel testing but a systematic comparison of these methods has not been reported in CUP. Furthermore, WGS has been largely restricted to using fresh tissues, limiting test access in many centres.
Methods
Whole-genome and transcriptome sequencing (WGTS) was applied to 75 CUP tumours (71 with matched panel), with 61 (81%) involving formalin-fixed paraffin embedded (FFPE) tissues. Diagnostic features (e.g. driver mutations, mutation signatures) were used to inform TOO diagnosis with clinicopathological review. Treatment targets were identified based on standard of care and clinical trials. The CUP Prediction Algorithm (CUPPA) utilising genome-wide DNA and RNA features was used to determine likely TOO and results compared to genome-informed pathology review. WGS and CUPPA was tested on 22 cell-free DNA (cfDNA) samples with tumour-fraction >8%.
Results
WGTS was successful for 73/75 tissue samples finding additional diagnostic features over panel in 20/71 (28%) cases and assisting a clinicopathological diagnosis in 48/73 (66%) overall. Treatment targets were found in 50/73 (68%) cases including mutation features in 21/71 (30%) not found by panel. High-likelihood CUPPA predictions were concordant with pathology review in 41/53 (77%) cases and none were discordant with pathology opinion. Additional high-likelihood CUPPA predictions were made in 9/20 (45%) cases otherwise deemed diagnostically unresolved. Applying WGS to cfDNA, CUPPA predictions were concordant with a pathological diagnosis in 9/11 (81%) cases, while 4/11 (36%) had high-likelihood predictions but TOO was pathologically undiagnosed.
Conclusions
WGTS is feasible using FFPE samples and diagnostically superior to panel sequencing. The curation of diagnostic features combined with CUPPA prediction can inform TOO in 74% CUPs by WGTS. Use of high tumour-fraction cfDNA may increase access to WGS and TOO prediction in some patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peter MacCallum Cancer Centre.
Funding
National Health and Medical Research Council, Victorian Cancer Agency, Medical Research Future Fund/Department Industry (Australian Federal Government).
Disclosure
D.D.L. Bowtell: Financial Interests, Personal, Other, Personal consulting fees (that are outside the submitted work): Exo Therapeutics; Financial Interests, Institutional, Other, Patent application to be submitted (unrelated to the submitted work).: Henry Jackson Foundation INOVA HealthCare University of Melbourne; Financial Interests, Institutional, Funding, Research support paid to my institution.: Roche/Genentech, AstraZeneca, BeiGene. S.M. Grimmond: Financial Interests, Personal, Invited Speaker, Precision Oncology Symposium Speaker 2024: AstraZeneca. L. Mileshkin: Financial Interests, Personal, Advisory Board, Participation in Dostarlimab advisory board: GSK; Financial Interests, Institutional, Coordinating PI, Institutional funding from BeiGene for an investigator-initiated trial: BeiGene; Financial Interests, Personal, Coordinating PI, Support for flights to attend ESMO meetings in Madrid and Singapore to present results of the CUPISCO trial: Roche; Financial Interests, Personal, Other, Medical writing support for publications related to the CUPISCO trial: Roche; Non-Financial Interests, Other, Co-chair of the Steering Committee for the CUPISCO trial in CUP (non-remunerated): Roche; Non-Financial Interests, Member, Member of multiple other cancer organisations as above: ASCO, MOGA, COSA, IGCS, GCIG. All other authors have declared no conflicts of interest.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07